Ceapro Inc V.CZO

RE:Why is AEZS trading below the cash value?

[prophetoffactz]

fossi, "Why does it take so long to find a new partner for the US market?"

It is very troubling that after nearly three months since the announcement of the proposed merger that fossi, the one who knows more than Ronnie Miller and the universal recommendation of the Board of Directors, etc., still hasn't figured that out. I've talked repeatedly about AEZS's pediatric clinical trial that was expected to be fully enrolled by the end of 2023. Childhood data should be imminent. AEZS has talked about the pediatric clinical tral driving deals. fossi appears totally clueless that awareness of the need for growth hormone deficiency testing is highest in children making children a key market for the test. Clinical tral data is imminent. Why can't fossi figure out the devastating consequences to children who suffer from growth hormone deficiency? Being able to market the test to the childhood market for the first time is expected to be able to increase awareness in the adult market for the test further growing the adult market. While adults suffer from a lack of awareness of the need for a growth hormone deficiency test a lack of the hormone in adults can change body composition, muscle tone, cardiovascular parameters, quality of life and mortality. Many adults are also recommended against the insulin tolerance test given diabetes and heart disease. Children will also be able to benefit from fewer of needle sticks, and less side-effects. Currently two growth hormone deficiency tests are required to make a diagnosis of growth hormone deficiency. AEZS's pediatric clinical trial is also set up such that its test may be the only test needed making it a further game changer in diagnosis. The requirement of having to use two tests to make a diagnosis may be ditched.

Copilot:

 Aeterna Zentaris has been actively involved in the development of diagnostic tools for growth hormone deficiency (GHD), particularly in children. Their focus on the childhood-onset GHD (CGHD) market is indeed significant. Here are some key points:

1. CGHD Diagnosis with Macimorelin:

   • Aeterna Zentaris has developed a method to measure growth hormone levels in children using macimorelin, an orally administered agent.
   • The process involves collecting blood samples within 60 minutes after administering macimorelin.
   • If the peak growth hormone level falls below a certain threshold, it indicates pituitary-related GHD1.

2. DETECT-Trial for CGHD Diagnosis:

   • A pivotal Phase 3 DETECT-trial is underway to investigate the efficacy and safety of a single oral dose of 1.0 mg/kg macimorelin acetate as a growth hormone stimulation test in pediatric patients with suspected GHD.
   • The study aims to enroll approximately 100 children and adolescents aged two to less than 18 years with suspected GHD23.

3. Importance of CGHD Diagnosis:

   • CGHD is an endocrine condition associated with various health issues from childhood through adulthood.
   • Proper diagnosis during the transition from adolescence to young adulthood is crucial.
   • The potential annual market for CGHD tests is estimated to be around 27,000 to 28,800 tests4.

In summary, Aeterna Zentaris recognizes the significance of the childhood market in the context of growth hormone deficiency diagnosis, and their efforts in this area are aimed at improving patient outcomes and addressing unmet medical needs.